(Q44780665)

English

Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain

scientific article published on 19 June 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Martine Braibant

1

object named as

Martine Braibant

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

Jing Xie

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Assia Samri

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Henri Agut

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Brigitte Autran

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Francis Barin

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

language of work or name

0 references

publication date

19 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

405

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

81-92

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Challenges in the development of an HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Characteristics of the env genes of HIV type 1 quasispecies in long-term nonprogressors with broadly neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Entire genome of a strain of human immunodeficiency virus type 1 with a deletion of nef that was recovered 20 years after primary infection: large pool of proviruses with deletions of env.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Coinfection and superinfection in patients with long-term, nonprogressive HIV-1 disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Longitudinal Analysis ofnef/Long Terminal Repeat–Deleted HIV‐1 in Blood and Cerebrospinal Fluid of a Long‐Term Survivor Who Developed HIV‐Associated Dementia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

HIV-1 Nef: at the crossroads

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

The structure of HIV-1 genomic RNA in the gp120 gene determines a recombination hot spot in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Dissection of a circumscribed recombination hot spot in HIV-1 after a single infectious cycle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Structure--function relationships in HIV-1 Nef.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Replication-dependent pathogenicity of attenuated nef-deleted HIV-1 in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

A patient with HIV-1 superinfection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Evolutionary and immunological implications of contemporary HIV-1 variation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

HIV-1 accessory proteins--ensuring viral survival in a hostile environment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Combination of HIV‐1–Specific CD4 Th1 Cell Responses and IgG2 Antibodies Is the Best Predictor for Persistence of Long‐Term Nonprogression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

One step forward, two steps back--will there ever be an AIDS vaccine?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Characterization of immune escape viruses from a macaque immunized with live-virus vaccine and challenged with pathogenic SHIVKU-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Immune-driven recombination and loss of control after HIV superinfection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Toward an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.05.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2010.05.026

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

release_c3musmc4lvb7zfq32dpdeurqsi

1 reference

https://api.fatcat.wiki/v0/release/c3musmc4lvb7zfq32dpdeurqsi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44780665&oldid=2041072667"